Intellia Therapeutics, Inc. (NTLA) KPIs and segments
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Intellia Therapeutics's business
Coming soon
This tab will track the numbers specific to Intellia Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?